A Phase I trial of PB2452 (MEDI2452)

Trial Profile

A Phase I trial of PB2452 (MEDI2452)

Phase of Trial: Phase I

Latest Information Update: 30 Nov 2017

At a glance

  • Drugs PB 2452 (Primary)
  • Indications Haemorrhage
  • Focus Adverse reactions
  • Most Recent Events

    • 30 Nov 2017 New trial record
    • 28 Nov 2017 According to a PhaseBio Pharmaceuticals media release, the company is planning to initiate this trial in the first half of 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top